Tolvaptan use tied to changes in mineral metabolism parameters and increased BMD in polycystic kidney disease

Switzerland: Chronic treatment with Tolvaptan is tied to an increased femoral bone mineral density (BMD), and remarkable changes in both acid-base parameters and mineral metabolism in patients with...

Related Keywords

Bern ,Switzerland ,Bruno Vogt ,Matteo Bargagli ,Nicolas Faller ,Danielg Fuster ,Andri Vetsch ,Manuela Anderegg ,Duyen Huynh ,Nassera Dhayat ,Pietro Manuel Ferraro ,University Of Bern ,Uyen Huynh Do ,Nephrology Dialysis Transplantation ,Bone Mineral Density ,Mineral Metabolism ,Olvaptan ,Autosomal Dominant Polycystic Kidney Disease ,Adpkd ,Demoral ,Chronic Treatment ,Henotype ,Polycystic Kidney Disease ,